-
COST-EFFECTIVENESS OF EZETIMIBE PLUS MODERATE-INTENSITY STATIN VERSUS HIGH-INTENSITY STATIN MONOTHERAPY FOR PRIMARY PREVENTION OF ASCVD IN TAIWAN
Aug 11, 2026, 17:16 PM -
DO REGULATORY AND INNOVATION PROXIES TRANSLATE INTO HTA VALUE? EVIDENCE FROM PORTUGAL
Aug 11, 2026, 17:16 PM -
INTERNALLY VALIDATED PREDICTION OF SEVERE HEALTH UTILITY IMPAIRMENT AMONG ADULTS REPORTING DEPRESSION IN THE EU5
Aug 11, 2026, 17:16 PM -
COMPARATIVE EFFICACY AND SAFETY OF ORFORGLIPRON VS SGLT-2 INHIBITORS FOR THE TREATMENT OF INSUFFICIENTLY CONTROLLED TYPE 2 DIABETES AS AN ADD-ON TO BACKGROUND THERAPY OF 1-2 ORAL ANTIDIABETIC DRUGS: A NETWORK META-ANALYSIS
Aug 11, 2026, 17:16 PM -
BEYOND CLINICAL OUTCOMES: A PATIENT AND FAMILY CO-CREATED VALUE FRAMEWORK TO CAPTURE THE FULL IMPACT OF CHRONIC CHILDHOOD DISEASE
Aug 11, 2026, 17:16 PM -
TOWARDS MORE TRANSPARENT DECISION MAKING AND FASTER PATIENT ACCESS: INTEGRATING UNMET MEDICAL NEED IN MARKET ACCESS FOR INNOVATIVE MEDICINES
Aug 11, 2026, 17:16 PM -
COST-EFFECTIVENESS ANALYSIS OF EARLY IMMUNOTHERAPY AND TARGETED THERAPY FOR NSCLC IN BULGARIA
Aug 11, 2026, 17:16 PM -
FACTUAL OR EVALUATIVE? HOW THE LANGUAGE OF JOINT CLINICAL ASSESSMENT REPORTS SHAPES NATIONAL APPRAISAL
Aug 11, 2026, 17:16 PM -
HOSPITAL CAPACITY USE IN DIFFUSE LARGE B-CELL LYMPHOMA CARE: A POPULATION-BASED TREATMENT-PATHWAY MODEL
Aug 11, 2026, 17:16 PM -
TRENDS IN GLP-1 RECEPTOR AGONIST UTILIZATION, EXPENDITURE, OUT-OF-POCKET BURDEN, AND FINANCIAL TOXICITY AMONG US ADULTS, 2017-2023
Aug 11, 2026, 17:16 PM -
WHAT DO THE FIRST EU JOINT CLINICAL ASSESSMENT COHORTS REVEAL ABOUT FUTURE EVIDENCE EXPECTATIONS? EARLY INSIGHTS FOR MANUFACTURERS AND HTA STAKEHOLDERS
Aug 11, 2026, 17:16 PM -
MEASURING RETURN ON INVESTMENT IN REAL-WORLD DATA, EVIDENCE, AND INSIGHTS: RESULTS FROM THE 2025 REAL-WORLD LEADERS FORUM BENCHMARK SURVEY
Aug 11, 2026, 17:16 PM -
FORGONE HEALTH FROM RESTRICTED ONCOLOGY ACCESS UNDER MOST-FAVORED-NATION PRICING: A TWO-MARGIN FRAMEWORK WITH A BREAST CANCER ILLUSTRATION
Aug 11, 2026, 17:16 PM -
DEVELOPING A MULTI-COUNTRY MICROSIMULATION TO ESTIMATE THE FUTURE IMPACT OF GUIDELINE-DIRECTED MEDICAL THERAPY ON POTENTIALLY AVOIDABLE HOSPITALISATIONS AND RELATED ECONOMIC, SOCIETAL, AND ENVIRONMENTAL OUTCOMES: GLOBALPAH
Aug 11, 2026, 17:16 PM -
DOES IRELAND NEED GENETIC TESTING? A HEALTH ECONOMICS PERSPECTIVE ON IRISH PRESCRIBING TRENDS, ADVERSE DRUG REACTIONS AND THE IMPACT OF PHARMACOGENOMIC TESTING
Aug 11, 2026, 17:16 PM -
BUDGET IMPACT OF SEMAGLUTIDE LOSS-OF-EXCLUSIVITY IN TYPE 2 DIABETES IN CANADA
Aug 11, 2026, 17:16 PM -
SOCIOECONOMIC INEQUALITIES IN UNMET DENTAL CARE NEEDS IN GREECE: EVIDENCE FROM EU-SILC 2024
Aug 11, 2026, 17:16 PM -
ADDRESSING EVIDENCE GAPS THROUGH STRUCTURED EXPERT ELICITATION: INSIGHTS FROM RECENT NICE TECHNOLOGY APPRAISALS
Aug 11, 2026, 17:16 PM -
EQUITY GAPS IN ACCESS TO ESSENTIAL CARDIOVASCULAR AND ANTIDIABETIC MEDICINES IN PAKISTAN: A MULTI-REGIONAL WHO/HAI SURVEY WITH MULTIVARIABLE ANALYSIS
Aug 11, 2026, 17:16 PM -
A POOLED REAL-WORLD CASE ANALYSIS OF BIOMARKER-GUIDED TREATMENT PATTERNS AND CLINICAL BURDEN IN BING-NEEL SYNDROME
Aug 11, 2026, 17:16 PM
